NeXT Personal for Ultra-sensitive MRD Detection & Response Monitoring

Time: 12:00 pm
day: Day One


  • Tumor-informed whole genome sequencing based technology with superior sensitivity and high specificity
  • Clinical Evidence from TRACERx demonstrating the applicability of NeXT Personal in early stage lung cancer
  • How ultra-sensitivity matters and is clinically meaningful